Merck Fosamax
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A two-year study of 10 mg alendronate daily in 241 men with osteoporosis shows mean bone mineral density increases of 7.1±0.3% at the lumbar spine, 2.5±0.4% at the femoral neck, and 2.0±0.2% for the total body. Placebo patients saw a 1.8±0.5% increase in BMD at the lumbar spine and no significant changes in femoral neck or total body BMD, investigators reported in the New England Journal of Medicine Aug. 31. The results were similar to one-year data announced last fall. Merck has an sNDA with priority review status pending at FDA for treatment of male osteoporosi
You may also be interested in...
Roche/Genentech Keeps Commitment To External Cancer Innovation
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
Unprecedented To Lawful: Regulatory Precedent Needed For Cannabinoids’ Use In Supplements?
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: